Ganaxolone

Drug Profile

Ganaxolone

Alternative Names: CCD-1042; Ganaxalone IV; Ganaxolone IV; gnx

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Purdue Pharma
  • Developer Marinus Pharmaceuticals
  • Class Antiepileptic drugs; Antimigraines; Neuroprotectants; Pregnanes; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Status epilepticus; Infantile spasms; Fragile X syndrome; Epilepsy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Partial epilepsies
  • Phase II Epilepsy; Fragile X syndrome; Lennox-Gastaut syndrome
  • Phase I Status epilepticus
  • No development reported Post-traumatic stress disorders
  • Discontinued Infantile spasms

Most Recent Events

  • 06 Jan 2017 Marinus Pharmaceuticals terminates a phase III extension trial for Partial epilepsies (Adjunctive treatment) in USA (NCT02519439)
  • 03 Jan 2017 Ganaxolone receives Orphan Drug status for Fragile X syndrome in USA
  • 15 Nov 2016 Pharmacodynamic data from a preclinical study presented at the 46th Annual Meeting of the Society for Neuroscience (SFN-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top